

# Jacques Hugon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3280778/publications.pdf>

Version: 2024-02-01

54  
papers

1,799  
citations

361413

20  
h-index

302126

39  
g-index

61  
all docs

61  
docs citations

61  
times ranked

2268  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. <i>Journal of Neurology</i> , 2022, 269, 44-46.	3.6	127
2	Long-COVID: Cognitive deficits (brain fog) and brain lesions in non-hospitalized patients. <i>Presse Medicale</i> , 2022, 51, 104090.	1.9	22
3	Rheumatoid arthritis and cognitive decline. <i>Joint Bone Spine</i> , 2022, 89, 105346.	1.6	7
4	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. <i>Alzheimer's and Dementia</i> , 2022, 18, 2537-2550.	0.8	21
5	Cognitive decline and brainstem hypometabolism in long COVID: A case series. <i>Brain and Behavior</i> , 2022, 12, e32513.	2.2	29
6	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	2.7	19
7	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3136.	4.1	17
8	Dose-dependent neuroprotective effect of the JNK inhibitor Brimapitide in 5xFAD transgenic mice. <i>Brain Research</i> , 2020, 1727, 146587.	2.2	6
9	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	6.2	20
10	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. <i>Immunology Letters</i> , 2020, 228, 129-134.	2.5	38
11	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	8.4	39
12	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	6.2	7
13	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037097.	0.8	0
14	STAT3 inhibition reverses neuroinflammation and A $\beta$ 2 metabolism induced by systemic inflammation. <i>Alzheimer's and Dementia</i> , 2020, 16, e041019.	0.8	4
15	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.1	50
16	Title is missing!. , 2020, 17, e1003289.		0
17	Title is missing!. , 2020, 17, e1003289.		0
18	Title is missing!. , 2020, 17, e1003289.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 17, e1003289.		0
20	Title is missing!. , 2020, 17, e1003289.		0
21	Title is missing!. , 2020, 17, e1003289.		0
22	Title is missing!. , 2020, 17, e1003289.		0
23	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of $\beta$ -amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
24	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell, 2019, 18, e12887.	6.7	28
25	CSF level of $\beta$ -amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
26	O <sub>5</sub> : CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.8	2
27	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience, 2019, 420, 136-144.	2.3	25
28	Could ryanodine receptor dysfunction be linked to PKR brain accumulations in Alzheimer's disease?. Medical Hypotheses, 2018, 113, 45.	1.5	1
29	P1 <sub>092</sub> : NEUROPROTECTIVE EFFECTS OF PKR KNOCKOUT IN 5XFAD ALZHEIMER MICE AND NEURON-MICROGLIA CO-CULTURES. Alzheimer's and Dementia, 2018, 14, P306.	0.8	0
30	Blood-Based Kinase Assessments in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	3.4	11
31	PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease. Experimental Neurology, 2018, 307, 62-73.	4.1	36
32	[P1 <sub>240</sub> ]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P336.	0.8	1
33	[P1 <sub>115</sub> ]: THE KINASE PKR INTERFERES WITH BRAIN AMYLOID ACCUMULATION IN 5XFAD MICE. Alzheimer's and Dementia, 2017, 13, P284.	0.8	0
34	[P2 <sub>211</sub> ]: AMYLOID $\beta$ 42 ( $A\beta$ 42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.	0.8	0
35	Dual Kinase Inhibition Affords Extended in Vitro Neuroprotection in Amyloid- $\beta$ Toxicity. Journal of Alzheimer's Disease, 2016, 54, 1659-1670.	2.6	11
36	Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. Journal of Alzheimer's Disease, 2016, 53, 1411-1418.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Neuroinflammation and A $\beta$ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. Scientific Reports, 2015, 5, 8489.	3.3	70
38	P4-313: Marked neuroprotection using dual kinase inhibition in A $\beta$ neurotoxicity: A new bitherapy. , 2015, 11, P904-P904.		0
39	Cerebrospinal fluid amyloid- $\beta$ 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
40	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. Cortex, 2015, 65, 89-101.	2.4	19
41	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. Journal of Psychiatry and Neuroscience, 2015, 40, 151-161.	2.4	75
42	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
43	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. Journal of Alzheimer's Disease, 2014, 40, 857-861.	2.6	22
44	P2-114: BRAIN AND CEREBROSPINAL FLUID C-JUN N TERMINAL KINASE 3 LEVELS IN ALZHEIMER'S DISEASE: LINKS TO COGNITIVE DECLINE. , 2014, 10, P512-P513.		0
45	P2-113: CSF AMYLOID- $\beta$ 42/40 RATIO IN CLINICAL SETTINGS: A MULTICENTRIC STUDY. , 2014, 10, P512-P512.		0
46	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. PLoS ONE, 2013, 8, e53587.	2.5	46
47	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 $\gamma$ pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 885-896.	3.8	139
48	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52
49	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. Brain Pathology, 2011, 21, 189-200.	4.1	55
50	PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. Journal of Cellular and Molecular Medicine, 2009, 13, 1823-1832.	3.6	27
51	The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation. FEBS Letters, 2007, 581, 4473-4478.	2.8	66
52	Upstream Signaling Pathways Leading to the Activation of Double-stranded RNA-dependent Serine/Threonine Protein Kinase in $\beta$ -Amyloid Peptide Neurotoxicity. Journal of Biological Chemistry, 2003, 278, 49819-49827.	3.4	87
53	Phosphorylation of eukaryotic initiation factor-2 $\gamma$ (eIF2 $\gamma$ ) is associated with neuronal degeneration in Alzheimer's disease. NeuroReport, 2002, 13, 2429-2432.	1.2	258
54	Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2 $\gamma$ in neuronal degeneration. Journal of Neurochemistry, 2002, 83, 1215-1225.	3.9	153